Brokerages Expect Humacyte, Inc. (NASDAQ:HUMA) to Post Quarterly Sales of $270,000.00

Analysts expect Humacyte, Inc. (NASDAQ:HUMA – Get a rating) will post sales of $270,000.00 for the current quarter, according to Zacks. Two analysts have released earnings estimates for Humacyte, with the lowest sales estimate at $130,000.00 and the highest estimate at $400,000.00. The company is due to release its next quarterly results on Monday, January 1.

On average, analysts expect Humacyte to register annual sales of $1.08 million for the current year, with estimates ranging from $550,000.00 to $1.60 million. For the next fiscal year, analysts expect the company to post sales of $15.95 million, with estimates ranging from $2.05 million to $29.85 million. Zacks sales averages are an average average based on a survey of research companies that provide coverage for Humacyte.

Humacyte (NASDAQ:HUMA – Get a rating) last released its results on Tuesday, March 29. The company reported earnings per share of $0.41 for the quarter, beating the consensus estimate of ($0.20) by $0.61.

Several research companies have recently published reports on HUMA. Piper Sandler reduced its target price on Humacyte from $17.00 to $10.00 in a Tuesday, March 29 report. Zacks Investment Research upgraded Humacyte from a “buy” rating to a “hold” rating in a Saturday, April 2 research report. One investment analyst has assigned the stock a hold rating and four have assigned the stock a buy rating. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $13.65.

(A d)

Take back your energy, go solar with American-made solar panels

Shares of HUMA opened at $7.37 on Friday. The company has a debt ratio of 0.40, a quick ratio of 20.75 and a current ratio of 20.75. The stock’s fifty-day simple moving average is $6.10 and its 200-day simple moving average is $7.88. Humacyte has a 12-month low of $4.37 and a 12-month high of $17.45.

A number of large investors have recently increased or reduced their stake in HUMA. Exos Asset Management LLC increased its position in Humacyte by 15.3% during the 1st quarter. Exos Asset Management LLC now owns 18,609 shares of the company worth $131,000 after purchasing an additional 2,470 shares last quarter. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in Humacyte in the first quarter worth approximately $48,000. BlackRock Inc. acquired a new stake in Humacyte in the fourth quarter valued at $10,158,000. Goldman Sachs Group Inc. acquired a new stake in Humacyte in the fourth quarter valued at $563,000. Finally, Virtu Financial LLC acquired a new equity stake in Humacyte during the fourth quarter at a value of $144,000. 6.92% of the shares are currently held by institutional investors.

About Humacyte (Get a rating)

Humacyte, Inc engages in the development and manufacture of ready-to-use, implantable, and bioengineered human tissues for the treatment of diseases and conditions in a range of anatomical locations across multiple therapeutic areas . The Company uses its proprietary, science-based technology platform to design and manufacture human acellular vessels (HAVs).

See also

Get a Free Copy of Zacks’ Research Report on Humacyte (HUMA)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings History and Estimates for Humacyte (NASDAQ:HUMA)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Humacyte right now?

Before you consider Humacyte, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Humacyte wasn’t on the list.

Although Humacyte currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Comments are closed.